Trial Profile
A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 Oral Solution in Patients With Parkinson's Disease of Moderate Severity Responding to Immediate-Release Oral Levodopa/Carbidopa and Withdrawn From Levodopa/Carbidopa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Zuranolone (Primary) ; Catechol O-methyltransferase inhibitors; Dopamine receptor agonists; Levodopa/carbidopa; Monoamine oxidase B inhibitors
- Indications Parkinson's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Biogen
- 02 Nov 2017 Top-line results for Part B published in a Sage Therapeutics Media Release.
- 20 Oct 2017 Status changed from recruiting to completed.
- 04 Aug 2017 According to a Sage Therapeutics Media Release, Part B study has been initiated.